Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by willibrichon Aug 14, 2010 1:23pm
823 Views
Post# 17351150

Indications of Mirador and other formation flow ra

Indications of Mirador and other formation flow raHere is some info on wells recently drilled into the Mirador,  and other  formations,  by companies in adjacent areas in the Llanos basin.

Parex Resources, PXT , released news on July  21, 2010  about successfull testing on their Kona 1 well. They will be pumping 3500 barrels per day from 47 feet of pay in the Mirador formation.

Canocol Energy, CNE , released news on July 27, 2010 about their RH-6 development well in the Rancho Hermosa field of the Llanos basin. This well was drilled to 10,780 feet and revealed  a total of 115 feet of pay spread out over  5 different formations. This press release goes on to detail flow rates from other development wells such as the RH-5 and RH-4.

Petrominerales, PMG,  reported on their Yenac -1 well on April 13, 2010. Previously I had noted a production of 1800 barrels per day from 42 feet of pay. This was incorrect. I had read an abbreviated news release.
PMG is actually producing 1800 barrels per day from 8 feet of sands at the top of the Mirador formation. The rest of the pay zone was too wet or had non-commercial 11 to 12 degree API oil.

It should be noted that flow rates from our well depend on many factors, as mentioned before. The important thing is that we have a new discovery well. After flow testing  of our Canaguay -1 well, we will know alot more about the reservoir. Our next well can then be better located. With each successfull development well, not only will production increase but  knowledge of the reservoir will increase.

And finally , remember that on the average only about 35 % of the oil in a reservoir can be recovered. And imagine our drill stem as a straw poked into the formation. If that straw happens to hit the '' sweet '' spot where pressures are greatest to allow for higher flow rates......................then so it goes.

   
Bullboard Posts